EASL 2022

EASL 2022
June 22-26, 2022
Virtual Conference

The International Liver Congress 2022: European Association for the Study of the Liver.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (11)

    Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H

    • Author(s): Mateo, R
    • bulevirtide
    • Liver Diseases

    Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment

    • Author(s): Hollnberger, J
    • bulevirtide
    • Liver Diseases

    Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis

    • Author(s): Gane, E
    • vemlidy
    • Liver Diseases

    Impact of patient-related factors on the pharmacokinetics of Bulevirtide

    • Author(s): Singh, R
    • bulevirtide
    • Liver Diseases

    Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

    • Author(s): Schwarz, K
    • vemlidy
    • Liver Diseases

    Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing

    • Author(s): Pan, D
    • viread
    • Liver Diseases

    Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study

    • Author(s): Wedemeyer, H
    • bulevirtide
    • Liver Diseases

    Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates

    • Author(s): Manhas, S
    • bulevirtide
    • Liver Diseases

    Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

    • Author(s): Levy, S
    • cilofexor/firsocostat/semaglutide
    • Liver Diseases

    Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases